When was Seaport Therapeutics founded?

Seaport Therapeutics was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Seaport Therapeutics located?

Seaport Therapeutics is headquartered in Boston, United States.

Who is the current CEO of Seaport Therapeutics?

Daphne Zohar of Seaport Therapeutics. They have also founded 2 companies and are an angel investors in 1 startup.

How many employees does Seaport Therapeutics have?

As of Sep 30, 2026, the latest employee count at Seaport Therapeutics is 75.

Is Seaport Therapeutics a funded company?

Seaport Therapeutics is a funded company, having raised a total of $325M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 09, 2024.

When was the latest funding round of Seaport Therapeutics?

Seaport Therapeutics' latest funding was a $***** Series B round on Oct 18, 2024, with participation from 8 investors.

Where does Seaport Therapeutics rank among its competitors?

Seaport Therapeutics ranks 5th amongst 101 active competitors, of which 22 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Enveda, which secured $311M in Sep, 2026.

Who are the top competitors of Seaport Therapeutics?

Seaport Therapeutics' top competitors include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Among them, Enveda secured the most recent funding round in September, 2026.

Seaport Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Seaport Therapeutics is a public company based in Boston (United States), founded in 2020 by Daphne Zohar and Steven Paul. It operates as a Developer of therapeutics to treat neuropsychiatric disorders. Seaport Therapeutics has raised $325M in funding from investors like General Atlantic, T. Rowe Price and Sofinnova Investments. The company has 101 active competitors, including 22 funded and 24 that have exited. Its top competitors include companies like Alto Neuroscience, Enveda and Vanda Pharmaceuticals.

Company Details

Developer of therapeutics to treat neuropsychiatric disorders. The company is advancing a pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph Technology which leverages the lymphatic system to create medicines building on clinically validated mechanisms. The company's product line include SPT-300 which is an oral prodrug of allopregnanolone, an endogenous neurosteroid, in development for the treatment of anxious depression.

Website: seaporttx.com
Social
Email ID: *****@seaporttx.com

Key Metrics

Founded Year

2020

Location

Boston, United States

Stage

Public

Total Funding

$325M in 2 rounds

Latest Funding Round

Series B, Oct 18, 2024, $*****

Investors

General Atlantic & 8 more

Ranked

5^th among 101 active competitors

Employee Count

75 as on Sep 30, 2026

Similar Companies

Alto Neuroscience & 129 more

Exit Details

Public

View Seaport Therapeutics' full profile

Seaport Therapeutics got listed on May 01, 2026.

Click here to take a look at Seaport Therapeutics's IPO in detail

Seaport Therapeutics has raised a total funding of $325M over 2 rounds. Its first funding round was on Apr 09, 2024. Its latest funding round was a Series B round on Oct 18, 2024 for $*****. 8 investors participated in its latest round. Seaport Therapeutics has 9 institutional investors.

Here is the list of recent funding rounds of Seaport Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 18, 2024	4121561	Series B	9061834	1309065	5710377	9840060
Apr 09, 2024	3679481	Series A	1695481	1374322	Arch Venture Partners & 1 more	Third Rock Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Seaport Therapeutics's funding rounds and investors

The founders of Seaport Therapeutics are Daphne Zohar and Steven Paul. Daphne Zohar is the CEO of Seaport Therapeutics.

Here are the details of Seaport Therapeutics' key team members:

Daphne Zohar: Co-Founder & CEO of Seaport Therapeutics and founder of 2 other companies, Nybo Therapeutics and PureTech Health. They are also an angel investor in 1 startup.
Contact Info: 4 email addresses
Steven Paul: Co-Founder of Seaport Therapeutics.

View details of Seaport Therapeutics's Founder profiles and Board Members

Seaport Therapeutics' employee count trend

Seaport Therapeutics has 75 employees as of Sep 26. Here is Seaport Therapeutics's employee count trend over the years:

Employee count trend for Seaport Therapeutics

Uncover Seaport Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Seaport Therapeutics include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Here is the list of Top 10 competitors of Seaport Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alpha Wave Global & 36 others	68/100
2nd	Enveda 2019, Boulder (United States), Series E	AI-based platform to decipher the chemistry of nature and develop new medicines	$845M	Premji Invest, Kinnevik & 36 others	63/100
3rd	Vanda Pharmaceuticals 2003, Washington, DC (United States), Public	Developer of pharmaceutical products for treating CNS disorders	$33.5M	Domain Associates, MedImmune Ventures & 4 others	63/100
4th	Beckley Psytech 2019, Oxford (United Kingdom), Series B	Developer of rapid-acting psychedelic medicines for mental health disorders	$153M	ATAI, Bain Capital & 28 others	62/100
5th	Seaport Therapeutics 2020, Boston (United States), Public	Developer of therapeutics to treat neuropsychiatric disorders	$325M	T. Rowe Price, Foresite Capital & 7 others	62/100
6th	Supernus Pharmaceuticals 2005, Rockville (United States), Public	Innovating CNS treatments, improving lives through neurological and psychiatric solutions	-	Abingworth, Westwicke & 6 others	59/100
7th	HMNC Brain Health 2010, Munich (Germany), Series B	Developer of targeted therapies for depression and other neuropsychiatric disorders	$41.5M	Maschmeyer Group, Kompernass & 10 others	55/100
8th	Neurovance 2011, Cambridge (United States), Acquired	Drug to modulate neurochemicals to treat Attention Deficit Hyperactivity Disorder .	$53M	GBS, Novartis Venture Fund & 3 others	53/100
9th	Reviva Pharmaceuticals 2006, San Jose (United States), Public	Develops therapeutic drugs for treatment of central nervous system	$41.5M	Lynx Financial	53/100
10th	Newleos 2009, Boston (United States), Series A	Developer of oral small molecules for neuropsychiatric conditions treatment	$93.5M	Goldman Sachs Asset Management, Longwood Fund ... & 3 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Seaport Therapeutics's competitors? Click here to see the top ones

Seaport Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Seaport Therapeutics's sector:

Free

Neurology - Sector Report

Edition: September, 2026 (73 Pages)

View all reports related to Seaport Therapeutics

Media has covered Seaport Therapeutics for a total of 16 events in the last 1 year, 8 of them have been about company updates and 2 about people movement.